Introduction {#Sec1}
============

Malignant melanoma is one of the most fatal skin tumors with a consistent increase of incidence reported over the last 3 decades \[[@CR1]\]. The data from the World Health Organization (WHO) show that every year 132,000 new cases of this neoplasm are diagnosed around the world \[[@CR2]\]. For years, prognosis for patients with unresectable stage III--IV tumors was poor. Responses to systemic therapy, with the exception of the small group of patients reacting well to high doses of interleukin 2 (IL-2), were unsatisfactory \[[@CR3], [@CR4]\]. During the last years, significant progress has been made in the development of new targeted therapies and immunotherapies \[[@CR5]\], which has given hope to patients with advanced stage malignant melanoma and markedly changed the future directions of progress in contemporary oncology. Although new treatments have already been introduced with many studies confirming their effectiveness, other therapeutic options are still needed for this group of patients.

In this review, we have presented current trends in the development of therapy for malignant melanoma and its future potential impact on the survival of patients with this tumor.

Methods {#Sec2}
=======

For the purpose of this report, the PubMed and ClinicalTrials.gov database were searched (Fig. [1](#Fig1){ref-type="fig"}). Articles were included for analysis if they concerned the following malignant melanoma treatments: oncolytic immunotherapy (e.g., talimogene laherparepvec and other oncolytic viruses), selective inhibitors of indoleamine 2,3-dioxygenease (e.g., epacadostat, indoximod), anti-PD-(L)1 (programmed death ligand 1) (e.g., atezolizumab), immune checkpoint protein LAG-3 (lymphocyte-activation gene 3) antibodies (e.g., relatlimab, eftilagimod alpha, LAG525), selective histone deacetylase (HDAC) inhibitors (e.g., entinostat), B7H3 inhibitors (e.g., enoblituzumab) and selected combinations of the above-mentioned therapies with other medications. The research data had to be published and available before 31 December 2018. Reports were excluded if they contained a description of current standard therapy of advanced melanoma, such as: checkpoint inhibitors---anti-PD1 antibodies (nivolumab and pembrolizumab), anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) immunoglobulin (ipilimumab) and targeted therapy (BRAF inhibitor, MEK inhibitor) unless these therapies were used in combination with previously mentioned drugs. Additional articles were included manually during investigation of papers' references if they were found relevant for current review. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.Fig. 1Process of searching the PubMed database (*BRAF* B-Raf proto-oncogene, *MEK* mitogen-activated protein kinase, *PD1* programmed cell death protein 1, *CTLA4* cytotoxic T-lymphocyte associated protein 4)

Talimogene Laherparepvec and Other Oncolytic Viruses {#Sec3}
----------------------------------------------------

The development of oncolytic immunotherapy has resulted in a promising treatment strategy, which in the future could yield improvement of the overall survival of patients with metastatic or unresectable malignant melanoma \[[@CR6], [@CR7]\]. Oncolytic viruses (OVs) act through selective infection and lysis of tumor cells as well as enhancement of the anti-tumor immune response \[[@CR8]\].

Talimogene laherparepvec (T-VEC) is the first and currently the only oncolytic herpes simplex virus type 1 (HSV1) used for the treatment of inoperable stage III and IV malignant melanoma approved by the FDA (Food and Drug Administration). To prevent toxicity, which was until recently a significant limitation associated with a therapeutic viral infection, HSV1 has been genetically modified to achieve T-VEC. Inactivation of neurovirulence factor ICP34.5 resulted in increased replication of the virus in tumor cells and reduced pathogenicity through the protection of normal cells \[[@CR9]\]. This effect is enhanced by simultaneous insertion of the US11 gene \[[@CR10]\]. Further modification by deleting the ICP47 gene allows the presentation of an antigen that has previously been inhibited by the virus \[[@CR11]\]. T-VEC also has the ability to express GM-CSF, which potentially augments the systemic T-cell immune response of the host to neoplasm cells \[[@CR12]\].

As mentioned above, the T-VEC mode of action is defined by two mechanisms: selective infection and termination of tumor cells as well as the induction of local and distant anti-tumor host immunity. In studies carried out by Kaufman et al. in patients with unresectable stage IIIc and IV metastatic melanoma, it was found that injected melanoma lesions showed an increase of MART-1 (melanoma-associated antigen recognized by T cells) specific CD8+ T cells and a significant decrease of suppressive immune cells \[[@CR13]\]. It seems that these changes in the tumor microenvironment might be valid determinants of the therapeutic response.

In the randomized, open-label, phase 3 clinical trial (OPTiM), the effectiveness of T-VEC was compared with GM-CSF on a group of 436 randomly assigned patients with unresected, injectable, stage IIIB--IV malignant melanoma \[[@CR14]\]. Analysis of the durable response rate (DRR), which includes cases with complete response (CR) and partial response (PR) present for at least 6 months, showed that DRR in patients treated with T-VEC was significantly higher than in the GM-CSF group (16.3% vs. 2.1%, respectively). Based on this study, the FDA approved T-VEC for advanced malignant melanoma.

There is a possibility of combining OVs with chemotherapy, radiation therapy, targeted therapy or immunotherapy. Strategies of combination therapy could potentially revolutionize and widen the spectrum of available treatment options for patients with advanced malignant melanoma. The first randomized study with the aim to check the efficacy of T-VEC with and without an anti-CTLA-4 antibody, ipilimumab, revealed that the objective response rate was higher for simultaneous treatment compared with monotherapy \[[@CR15]\].

Furthermore, a multicenter phase 1B study (MASTERKEY-265) investigating the safety and tolerability of T-VEC with pembrolizumab in patients with stage IIIB--IV malignant melanoma also showed that combined treatment is associated with a clinical benefit \[[@CR16]\]. The subsequent randomized, double-blind phase 3 trial (KEYNOTE-034) evaluating T-VEC (versus T-VEC-placebo) plus pembrolizumab is ongoing, and the results are not available yet \[[@CR17]\].

There are also attempts to use T-VEC as a neoadjuvant therapy. The phase 2 study aimed to examine 150 patients with stage IIIB--IVM1a tumors before resection to evaluate the effectiveness of T-VEC treatment combined with surgical treatment compared with surgery alone. The results of this analysis have not yet been published \[[@CR18]\].

Currently, ongoing clinical trials evaluate several other OVs in the treatment of malignant melanoma including adenoviruses, Coxsackie viruses, reoviruses, polio viruses, measles virus, vesicular stomatitis virus, vaccinia virus, Sendai virus, Newcastle disease virus (NVD) and HSV1 \[[@CR19]\]. Although the number of the ever-tested OVs is high, in Table [1](#Tab1){ref-type="table"} we present those that probably should gain more clinical attention.Table 1Examples of oncolytic viruses tested for malignant melanoma treatmentOncolytic virusDescriptionResearch phaseResearch statusParticipantsResearch IDOutcomes*Coxsackie virus A21*Multicenter, open-label, phase 2 study in patients with stage IIIc and IV malignant melanomaPhase 2Completed57NCT01227551ORR rate was 28.1%\
Grade 1 AEs included: fatigue, chills, local injection site reactions and fever\
No grade 3 or 4 AEs were observedPhase 2 study in patients with stage IIIc--IV malignant melanoma to extend dosing for up to 48 weeksPhase 2Completed16NCT01636882CVA21 treatment increased immune cell infiltrates (CD3+ CD8 ) and expression of PD-L1\
SAEs and AEs were irrespective of treatment*Adenovirus*Phase 1/2, single-arm study of intratumoral injections in patients with inoperable stage III--IV melanomaPhase 1/2Completed14NCT01397708Treatment was well tolerated and induced biologic and clinical activity.\
AEs included chills (78.6%), pyrexia (78.6%), fatigue (71.4%) and nausea (71.4%)*ECHO 7 virus* (*Rigvir*^®^)A retrospective study to determine the efficacy of Rigvir^®^ in patients with IB--IIC malignant melanomaRegistered in LatviaNot applicable79PMC4560272Rigvir^®^ extended survival in patients with malignant melanoma\
AEs \> class 2 were absent*HF10*Phase 1, open-label multicenter study, evaluating intratumoral injections of the HF10 in refractory and superficial lesions (including malignant melanoma)Phase 1Completed28NCT01017185Six patients had AEs associated with HF10, including chills (two patients) and discolorations at the injection site, edema and pain, malaise, pruritus and hypotension (one patient each)*ORR* overall response rate, *AEs* adverse events, *SAEs* serious adverse events

Indoleamine-2,3-dioxygenase (IDO) Inhibitors {#Sec4}
--------------------------------------------

Selective inhibitors of indoleamine 2,3-dioxygenease (IDO) may be effective for the treatment of advanced and metastatic melanoma. IDO is a catabolic enzyme responsible for oxidation of tryptophan to *N*-formyl-kynurenine \[[@CR20]\]. Overexpression of this rate-limiting enzyme by malignant cells is involved in immune modulation because of its ability to inhibit T-cell immune responses and consequent tumor outgrowth. Overexpression of IDO is usually associated with a worse prognosis; thus, IDO is a promising therapeutic target, and the use of its inhibitors could significantly reduce cancer neovascularization and decrease the prevalence of metastasis. Presently, preclinical and clinical trials are underway for several IDO inhibitors \[[@CR21]\]. In Table [2](#Tab2){ref-type="table"}, we presented selected studies focused on IDO inhibitors as well as their combinations with other treatments for malignant melanoma.Table 2Clinical trials of indoleamine-2,3-dioxygenase (IDO) inhibitors in malignant melanomaAgentDescriptionResearch statusCombination withResearch IDOutcomesEpacadostatOpen-label dose escalation study in patients with advanced malignanciesCompleted--NCT01195311Doses of ≥ 100 mg BID caused maximal inhibition of IDO1 activity\
Treatment-related AEs in \> 20% of patients included: fatigue, nausea, decreased appetite, vomiting, constipation, abdominal pain, diarrhea, dyspnea, back pain and coughPhase 2 trial study of epacadostat and vaccine therapy in treating patients with stage III--IV malignant melanomaCompletedVaccine therapyNCT01961115Confirmed clinical activity and evidence of increased CD8 T-cell infiltration\
DLTs in 2 patients: grade 3 transaminase elevation, grade 3 syncopePhase 1 blinded research of ipilimumab with epacadostat (or placebo) in patients with inoperable or metastatic malignant melanomaTerminatedIpilimumabNCT01604889Seven patients received a dose of 300 mg BID; five of these patients had significant alanine aminotransferase activity elevation after 30--76 days\
Enrollment was prematurely stopped\
AEs were reversible with corticosteroids. Enrollment was restarted at 25 mg BID\
Combination of 25 mg epacadostat and ipilimumab could enhanced efficacy compared with ipilimumab monotherapyPhase 1b study evaluating efficacy of itacitinib + epacadostat and/or icacitinib + INCB050465 in advanced or metastatic solid tumorsActive, not recruitingItacitinibNCT02559492N/APhase 1 and 2 study evaluating combination of azacitidine with pembrolizumab and epacadostat in patients with advanced solid tumors, including melanomaActive, not recruitingAzacytidine + pembrolizumabNCT02959437N/AIndoximodPhase 1 trial investigating side effects and dose of indoximod in patients with metastatic or unresectable solid tumorsCompleted--NCT00567931Indoximod was safe at doses up to 2000 mg BID. ORR was 10%, AEs were: fatigue (56%), anemia and anorexia (37.5%), dyspnea (35.4%) cough (33.3%), nausea (29%)Phase 1 study of using indoximod for refractory solid tumors including malignant melanomaTerminated--NCT00739609Lack of enrollmentPhase 1 and 2 study of indoximod in combination with checkpoint inhibitors for patients with metastatic malignant melanomaActiveCheckpoint inhibitorsNCT02073123Combination of indoximod and pembrolizumab demonstrates an ORR of 55.7%, CR 18.6%, compared with reported 33% ORR for pembrolizumab alonePhase 2 and 3 assessing the efficacy of indoximod or placebo with pembrolizumab or nivolumab in patients with inoperable, metastatic malignant melanomaRecruitingPembrolizumab/NivolumabNCT03301636N/AIDO peptide vaccinePhase 1 research assessing efficacy of vaccination with peptides in combination with ipilimumab or vemurafenib for patients with unresectable stage III or IV malignant melanomaCompletedIpilimumab/VemurafenibNCT02077114Vaccine-related grade 1 and 2 AEs: erythema, edema and pruritus\
All AEs were manageable with corticosteroids\
No AEs grade 3 or 4Phase 2 study to examine treatment with peptide vaccine and temozolomide for metastatic melanoma patientsTerminatedTemozolomideNCT01543464Trial was terminated before full enrollmentPhase 1 and 2 trial of combination therapy with nivolumab and PD-L1/IDO peptide vaccine in patients with metastatic melanomaRecruitingNivolumabNCT03047928N/AGDC-0919Phase 1 study evaluating the safety, tolerability and doses of GDC-0919 for patients with malignant melanomaCompleted--NCT02048709Navoximod (GDC-0919) was well tolerated at doses up to 800 mg BID\
Grade ≥ 3 AEs related to navoximod occurred in 9% of patientsHTI-1090Phase 1 trial of HTI-1090 in patients with advanced solid tumorsRecruiting--NCT03208959N/ANLG802Phase 1 study examining the safety, tolerability and doses of NLG802 in patients with advanced solid tumorsRecruiting--NCT03164603N/ABMS-986205Phase 1 study evaluating the treatment of solid tumors with different combinations of immunotherapyRecruitingVarious combinations of immunotherapyNCT03335540N/A*AEs* adverse events, *DLTs* dose-limiting toxicities, *BID* twice daily, *N/A* not applicable, *ORR* overall response rate

Epacadostat (INCB024360) is a novel selective inhibitor of IDO1 with good oral bioavailability. A phase 1 dose-escalation study involving 52 participants with advanced malignancies was performed to determine the safety of epacadostat. The most common side effects were abdominal pain, fatigue and hypokalemia, including grade 3 and 4 adverse events. The study also identified 600 mg epacadostat as the recommended dose of the drug as monotherapy \[[@CR22]\]. Nevertheless, monotherapy with IDO1 inhibitors did not show marked clinical activity; therefore, further studies are ongoing to establish the best combination of epacadostat with other immunotherapies.

In a phase 1/2 randomized and placebo-controlled study, an attempt was made to combine epacadostat with ipilimumab. The 25-mg dose of epacadostat in combination with the standard dose of ipilimumab was generally well tolerated. Adverse effects were reversible with corticosteroids and discontinuation of treatment. This research allowed the conclusion that epacadostat might enhance clinical activity of ipilimumab \[[@CR23]\].

Epacadostat has also been evaluated in combination with pembrolizumab in reference to patients with advanced melanoma and other solid tumors. A phase 1/2, multicenter, nonrandomized, open-label study showed promising efficacy and durable antitumor activity. Unfortunately, phase 3 study did not meet the primary end point of improvement in PFS compared with pembrolizumab monotherapy \[[@CR24], [@CR25]\]. The reasons for this negative trial remain undetermined \[[@CR26]\]. Furthermore, other attempts were taken to assess the effectiveness of various drugs plus epacadostat, some of which are gathered in Table [2](#Tab2){ref-type="table"}.

Indoximod ([d]{.smallcaps}-1-methyl-tryptophan) is an orally available, indirect inhibitor of IDO1 and also a more selective IDO2 inhibitor of the indoleamine 2,3-dioxygenase pathway. Indoximod showed anti-tumor activity and synergistic action with various chemotherapeutics. The primary end point in the phase 1 study was to determine the maximal well-tolerated dose (MTD) in 48 patients with advanced malignancies. The dose ranged from 200 mg once a day to 2000 mg twice daily. Unfortunately, MTD has not been reached, but no significant increase in toxicity was observed between various doses, and no patients stopped treatment because of any toxicity. The authors concluded that indoximod was generally well tolerated \[[@CR27]\]. As in the case of epacadostat, antitumor activity of monotherapy with indoximod was unsatisfactory, and many combinations with other immunotherapies are being investigated (Table [2](#Tab2){ref-type="table"}).

The ineffectiveness of the IDO inhibitor as monotherapy can be associated with immune evasion of TRCs that lead to tumor recurrence, drug resistance and formation of metastasis. TRCs are self-renewing cancer cells similar to stem cells with the ability to repopulate tumors. Nonetheless, the combination of IFN-γ with IDO1 inhibitors is currently the only therapy that could potentially eliminate TRCs and thus may improve treatment outcomes. Given the TRC dormancy that was induced by IFN-γ and immunosuppression caused by IDO1, TRCs are vulnerable to attacks by T cells and NK cells, which makes this strategy of immunotherapy very promising \[[@CR28]\].

Anti-PD-(L)1-Programmed Death Ligand 1 {#Sec5}
--------------------------------------

Expression of an immune-checkpoint protein-PD-L1 on the surface of tumor cells could restrain T-cell function. PD-L1 binds to the PD-1 and B7.1 proteins. The PD-1/PD-L signaling pathway is one of the key mechanisms that could contribute to the inhibition of the antitumor response and thus protect tumor cells. The respective components of the PD-1/PD-L pathway are targets of immunotherapy with specific monoclonal antibodies. One of them is atezolizumab---an engineered humanized monoclonal anti-PD-L1 antibody \[[@CR29]\].

Monotherapy with atezolizumab will be investigated in a phase 1b study (NCT03178851) with the following evaluation criteria: the efficacy, safety and pharmacokinetics of this drug in patients with BRAFV600-WT metastatic malignant melanoma who have not been previously treated. This study will also assess the combination of cobimetinib and atezolizumab in patients who have worsened despite anti-PD-1 therapy.

Recent studies have shown that atezolizumab can act synergistically with MEK inhibitors, such as cobimetinib \[[@CR30]\]. Thus, it might be a potential therapeutic option for patients with metastatic malignant melanoma. Unfortunately, this combination has not been licensed yet for any indication in the EU. The phase 3, multicenter, randomized trial (NCT03273153) intended to measure the efficacy and safety of cobimetinib plus atezolizumab compared with pembrolizumab in previously untreated participants with advanced wild-type BRAFV600 melanoma. This study is currently in a recruitment phase. There have also been attempts to combine atezolizumab with cobimetinib and vemurafenib. Updated results confirm the preliminary data, which have shown a manageable safety profile \[[@CR31], [@CR32]\]. Continued investigation of this combination is justified.

LAG3 inhibitors {#Sec6}
---------------

Tumors have the ability to escape immune surveillance, and detailed knowledge of these mechanisms led to discoveries that signaling via specific receptors, such as LAG3 or PD1, could cause T-cell dysfunction \[[@CR33]\]. The first results of a clinical trial have shown that the concomitant usage of immune checkpoint protein LAG-3 antibodies, relatlimab and nivolumab, to increase the anti-tumor immunity by restoring the activation of T cells is safe and effective for patients who have progressed despite targeted immunotherapy. ORR was 11.5%; one patient achieved a complete response, and six had partial responses. In patients with LAG-3 expression ≥ 1%, ORR was higher. In this study, 4.4% of patients had one or more AEs in grade 3 or 4 associated with the treatment, and 1.5% had to stop the treatment because of AE \[[@CR34]\].

Under investigation is also IMP321-eftilagimod alpha, the first class MHC-II agonist that could potentially be used with other drugs. Phase 1 study (NCT02676869) of IMP321 in combination with pembrolizumab was performed to determine the safety, tolerability and recommended dose for phase 2 study on patients with stage III and IV malignant melanoma.

Moreover, another monoclonal antibody, LAG525, is currently being tested in a phase 1/2 clinical trial (NCT02460224). The main purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of LAG525 alone or with PDR001 (new anti-PD1 compound) in adult patients with solid tumors.

Inhibitors of Histone Deacetylase (HDAC) and B7-H3 {#Sec7}
--------------------------------------------------

Another promising therapy for patients who suffer from malignant melanoma unequivocally resistant to prior anti-PD-(L)1 treatment is the simultaneous administration of a class I selective histone deacetylase (HDAC) inhibitor, entinostat, with pembrolizumab. The purpose of this combination is to reinforce inflammation in the neoplasm microenvironment required for propitiously retreatment with an anti-PD(L)1. In a phase 1b/2 study, the predominant treatment-related AEs were nausea, fatigue, diarrhea and pruritus. Updated results confirm preliminary findings that entinostat plus pembrolizumab have a manageable safety profile \[[@CR35]\].

Furthermore, patients with B7-H3-expressing melanoma have been enrolled in a phase 1 study whose aim is to evaluate the safety of enoblituzumab (MGA271) with pembrolizumab. Enoblituzumab is a monoclonal antibody that has the ability to bind to B7-H3 (CD276). B7-H3 overexpression has been shown in many tumors, including melanoma; unfortunately, it is also associated with poor prognosis. On the other hand, B7-H3 shows limited expression in normal tissue, which may help to reduce the risk of AEs associated with autoimmunity. The NCT02475213 trial (a dose escalation, open-label and cohort expansion study) focuses on the evaluation of targeting both receptors, B7-H3 and PD-1, in patients with advanced B7-H3-expressing cancers \[[@CR36]\].

Future Directions {#Sec8}
-----------------

In our article, we have summarized a number of different treatment strategies currently under development for malignant melanoma. However, there are many unanswered questions that need to be addressed in the near future.

Regarding oncolytic viruses, future studies should focus on new potential combinations with other treatment modalities. Besides clinical trials evaluating combination with immune T-cell checkpoint inhibitors targeting CTLA-4 or PD-1, special attention should be given to a combination of available oncolytic virotherapies with radiation therapy, BRAF inhibitors, MEK inhibitors or adaptive T-cell therapy. Moreover, further investigations might evaluate the application of oncolytic viruses not only in melanoma therapy, but also in other skin tumors that are easily accessible for injections, such as Merkle cell tumors, squamous cell carcinoma or basal cell carcinoma. Studies should also focus on better understanding of the mechanisms underlying the anti-cancer immune response mediated by oncolytic viruses and on the assessment of prognostic biomarkers of therapeutic response; these are crucial for the proper identification of patients who could benefit from this type of therapy. This could also enable a better selection of patients for clinical trials and might help to reduce unnecessary expenses while such therapy is being approved for use.

Monotherapies do not always bring the desired results, as in the case of IDO inhibitors. However, combined therapies create the opportunity to widen the therapeutic window. IDO2 inhibitors could limit autoimmune-related adverse events caused by other cancer therapies. There is also quite strong evidence of the interaction among CTLA-4, PD-L1 and IDO. Holmgaard et al. have shown that IDO expression has an inhibitory role in both anti-CTLA-4 and anti-PD1/PD-L1 therapies \[[@CR37]\]. Despite so far unsuccessful clinical trials, investigation of the effect of IDO inhibitors, as part of combination strategies in malignant melanoma patients, is essential and should be further studied.

As in the case of many other immunotherapies, blockade of PD-L1 presented beneficial effects only in a subgroup of patients. The latest studies have shown that the efficacy of PD-L1 therapy could be improved by modulation of gut microbiota \[[@CR38]\]. Increased anti-PD-L1 efficacy was observed in mouse models after administration of Bifidobacterium \[[@CR39]\]. Future studies should concentrate on investigations of the molecular mechanisms of this action. Finally, the question of whether chronic infection or inflammation could impact the effectiveness of the PD-L1 blockade arises.

Furthermore, the current studies did not fully disclose the exact function of LAG-3. Comprehensive understanding of this action might have a tremendous impact on the indication of new therapeutic regimens. The heightened interest should not only concern combinatorial PD1 immunotherapy and LAG-3, but also other first-line treatment options with LAG-3 inhibitors.

Conclusions {#Sec9}
===========

In recent years, poor efficacy of the treatment of malignant melanoma has led to the continuation of research to better understand how to stimulate the anti-cancer immune response. As stated before, many clinical trials are still ongoing. The simplified action mechanisms of drugs that were considered in this review are presented in the Fig. [2](#Fig2){ref-type="fig"} below, and the summary of the discussed drugs is shown in Table [3](#Tab3){ref-type="table"}.Fig. 2Overview of action mechanisms of selected drugs that are under development for malignant melanoma therapy: (from left to right) relatlimab, a monoclonal antibody, binds to the LAG3 receptor, which is present on the surface of specialized immune cells, restoring its activity and allowing them to attack cancer cells; atezolizumab, a monoclonal antibody, binds to the PD-L1 on both tumor cells and immune cells, blocking its interactions with PD1 and B7.1 receptors and restoring T-cell activity; T-VEC presents a dual mechanism of action---selective viral replication results in lysis of tumor cells and production of GM-CSF by tumor cells upon T-VEC further leads to proliferation of CD4+ and CD8+ T-cell and IFN-γ expression; indoximod downregulates the IDO pathway, resulting in the immunostimulatory effect of CD4 + and CD8 + T cells and a decrease of Tregs; epacadostat inhibits the IDO1 enzyme, which leads to the restoration of CD8+ T-cell and CD4+ T-cell proliferation and a reduction of Tregs; entinostat works through the epigenetic mechanism of action involving histone acetylation and simultaneous acetylation of non-histone proteins---this dual mechanism causes an increase of the immune response and melanoma cell apoptosis (*T-VEC* talimogene laherparepvec, *LAG-3* lymphocyte activation gene 3, *PDL-1* programmed death ligand 1, *PD1* programmed cell death protein 1, *GM-CSF* granulocyte macrophage-colony-stimulating factor, *IDO1* indoleamine 2,3-dioxygenase 1, *IDO2* indoleamine 2,3-dioxygenase 2, *IFN-γ* interferon gamma; *Tregs* tumor-associated regulatory T cells) Table 3Summary of different immunotherapies being currently developedDrugMechanism of actionCommentsReferencesAtezolizumabBinding to the PD-L1 and further blocking its interaction with PD1 and B7.1\
Restoring T-cell activityAtezolizumab can act synergistically with MEK inhibitors\
Continued investigation of this drug in combination with other immunotherapies is required\[[@CR29]--[@CR32]\]EnoblituzumabDirect binding to B7-H3 over-expressed on tumor cells and cancer stem-like cellsThe drug is currently being tested in combination with pembrolizumab for patients with B7-H3-expressing melanomaNCT02475213 trialEntinostatHistone and non-histone acetylation. Increase of immune response and apoptosisEntinostat plus pembrolizumab achieved manageable safety profile\
Reinforcing of inflammation in the neoplasm microenvironment could improve retreatment with an anti-PD-L1 in patients with malignant melanoma\[[@CR35]\]EpacadostatSelective inhibition of IDO1 resulting in restoration of CD8 + T cells, proliferation of CD4 + T cells and reduction of TregsEpacadostat was generally well tolerated and might enhance activity of ipilimumab\
Monotherapy with epacadostat did not show marked clinical activity\
The attempt of simultaneous usage of epacadostat and pembrolizumab did not meet the primary end point\
Combinations with other immunotherapies are currently under investigation\[[@CR22]--[@CR26]\]IMP321---eftilagimod alphaStimulation of antigen-presenting cells and induction of sustained immune responsesThe addition of eftilagimod alpha might improve the objective response rates as compared with PD1 inhibitor monotherapy\
Clinical trials for patients with malignant melanoma are still ongoingNCT02676869 trialIndoximodIndirect suppression of IDO1 and more selective inhibition of IDO2 resulting in an increased number of CD8+ T cells, CD4+ T cells and a decrease of TregsIndoximod was generally well tolerated\
Antitumor activity as monotherapy was unsatisfactory\
Further investigations of combination of indoximod with other immunotherapies are pending\[[@CR27]\]LAG525Antibody-dependent cell cytotoxicity and T-cell stimulationThis monoclonal antibody is currently being tested to assess its safety and efficacy\
LAG525 has potential to change the tumor microenvironment to be more favorable for immune responseNCT02460224 trialRelatlimabBinding to the LAG3 receptor and restoring T-cell activitySimultaneous administration of relatlimab and nivolumab was well tolerated and effective\
Safety profile was similar to nivolumab monotherapy\[[@CR34]\]T-VECSelective infection and lysis of tumor cells, increase of GM-CSF production as well as induction of local and distant tumor specific immune responseT-VEC has a favorable safety profile and good efficacy in patients with unresectable malignant melanoma without distant metastases\
T-VEC can also be successfully combined with other immunotherapies to improve their efficacy\[[@CR9]--[@CR16]\]

We hope that novel treatment modalities for advanced malignant melanoma can lead to marked changes in this neoplasm therapy and significant improvement of the survival rate of patients with malignant melanoma.
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